Temporal changes of cardiac acoustic biomarkers and cardiac function in acute decompensated heart failure

ESC Heart Fail. 2021 Oct;8(5):4037-4047. doi: 10.1002/ehf2.13492. Epub 2021 Jun 28.

Abstract

Aims: Relationships between cardiac acoustic biomarkers (CABs) measured by acoustic cardiography and clinical outcomes have been reported in heart failure (HF) patients. However, no studies have investigated the temporal change of CABs and the corresponding changes in HF status. The purpose of this study was to assess whether the temporal changes of CABs in patients with acute decompensated heart failure (ADHF) reflect changes in cardiac function and status.

Methods and results: Sixty ADHF patients were enrolled prospectively. CABs and echocardiography data were collected at admission, before discharge, and at the first clinic visit. CABs included electromechanical activation time (EMAT); the time interval from Q wave onset on electrocardiography to the first heart sound (S1), QoS2; the time interval from Q wave onset on electrocardiography to the second heart sound (S2); and third heart sound (S3) and fourth heart sound (S4) intensities, defined as the peak-to-peak amplitudes of S3 and S4. EMATc (EMAT/RR) (P = 0.001), S3 intensity (P < 0.001), and S4 intensity (P < 0.001) were significantly decreased, and QoS2 (P = 0.005) was significantly increased from admission to discharge. The change in S3 intensity was significantly correlated with that of E/A (ρ = 0.571, P < 0.001), and the extended QoS2 was also significantly correlated with the increase in the stroke volume index (ρ = 0.383, P = 0.004).

Conclusions: Some CABs in ADHF patients changed significantly in the normal direction throughout the treatment course and could be useful biomarkers in ADHF management.

Keywords: Acoustic cardiography; Cardiac acoustic biomarkers; Heart failure; Heart sound.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acoustics
  • Biomarkers
  • Electrocardiography
  • Heart Failure* / diagnosis
  • Humans
  • Stroke Volume

Substances

  • Biomarkers